(Bloomberg) – Shares of companies that develop or manufacture therapies to combat viral outbreaks, such as SIGA Technologies Inc. And Emergent BioSolutions Inc. is rallying on Thursday in the United States for the first case of MonkeyPix this year, and new cases are emerging. United Kingdom
SIGA, a biological warfare defense firm, rose 23%, the biggest intra-day jump since 2016, when the threat of Zika infection was raging in the market. The company today received U.S. regulatory approval to enter the vein of its smallpox pill. The drug, called Tpoxx, has been approved for use in monkey pox in Europe and was cited in a recent budget request for the treatment of a US patient with the disease, the company said in a statement.
Contract manufacturer Emergency, which is facing congressional investigations into quality control problems in the production of the Covid-19 vaccine, has risen by 18%, its biggest one-day jump since March 2020. SIGA and Emergent may be familiar names to investors as they took big steps in 2014 to start a potential epidemic threat, such as Zika and Ebola, as well as the beginning of the Covid-19 epidemic.
Chimerix Inc., another antiviral drug developer, rose 14%, while Inovio – which was developing a Covid-19 vaccine before the U.S. government raised funds last year – rose 18%.
Rare and potentially dangerous monkeypox has been confirmed in the United States by a man who recently traveled to Canada, two news incidents occurred in the United Kingdom, bringing the total number there to nine. It follows reports of scattered cases in Europe.
© 2022 Bloomberg LP